Sentio hearing system studied in teenagers with hearing loss or deafness in one ear
Collects safety and performance information on the Sentio system in teenagers with hearing loss.
Key facts
- Who runs it
- Oticon Medical
- Where
- Atlanta, United StatesSee the site
- Trial code
- Registry title
- The Sentio System: Post-market Evaluation of Safety and Performance in Adolescents
- Status
- Recruiting
- People taking part
- 25 people, planned
- Started
- 15 Aug 2025
- Expected to end
- Aug 2027
- Type of study
- Observational
- Record updated
- 22 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers aged 12 to 17 with conductive or mixed hearing loss, or deafness in one ear. They will get the Sentio bone conduction hearing system.
- Age
- 12 to 17 years (inclusive)
- Sex
- All
- Disease stage
- Conductive or mixed hearing loss with a bone conduction average of 45 dB HL or better in the ear to be treated, and an air-bone gap large enough (e.g., >25 dB). Or profound hearing loss in one ear with normal hearing (20 dB HL or better) in the other ear. Or people who could use an AC CROS hearing aid but cannot or will not.
- Earlier treatment
- Must have used a properly fitted sound device before, such as a hearing aid, a CROS device, or a non-surgical bone conduction device (e.g., a softband or sound arc). Cannot join if radiotherapy was given, or is planned, in the implant area.
Main reasons for not taking part
- Health problems that rule out implant surgery or anaesthesia
- Untreated middle ear infection at the time of surgery
- Allergy to silicone or other materials in the Sentio system
- Bone or skull too thin or small for the implant
- Implanted or worn devices that cannot be removed, such as pacemakers or brain fluid shunts
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Subjects must meet the following criteria to be eligible for participation in the investigation:; Signed Informed Consent Form (signed by parent or legal guardian and child); Subjects aged 12 to 17 years of age (inclusive); Subjects with the following audiometric criteria consistent with the current and approved labeling of the device:; 3.1 Conductive or mixed hearing loss with a pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) of the indicated ear better than or equal to 45 dB HL; 3.2 OR subjects with a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing (AC) thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz); 3.3 OR subjects who are indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS; Prior experience with amplified sound through properly fitted amplification devices such as a hearing aid, a CROS device, or a non-surgical bone conduction solution (e.g., a softband or sound arc); For patients with conductive or mixed hearing losses sufficient (e.g., >25 dB) air bone gap (ABG) at the ear to be implanted; Subjects and parent(s) or legal guardian have the ability and willingness to comply with all investigational procedures/requirements, as determined by the Investigator
Who cannot take part
- Subjects meeting any of the following criteria will not be permitted to participate in the investigation:; Medical condition(s) that contraindicates implant surgery or anesthesia; Untreated ongoing middle ear infection at the time of surgery; Known or suspected contact allergy to silicone or other material used in the Sentio system; Insufficient bone quality/quantity/depth or skull size for implantation of a Sentio Ti implant, assessed according to clinical practice; Known conditions that could jeopardize wound healing and skin condition e.g. uncontrolled diabetes over time or skin or scalp condition(s) that may preclude attachment to, or interfere with usage of, the sound processor as judged by the investigator; Subject that has received radiotherapy in the area of implantation or is planned for such radiotherapy or similar during the investigation period; For bilateral asymmetric* candidates, subjects already treated with a bone-anchored hearing solution on the side with the best BC thresholds; Known chronic or non-revisable vestibular or balance disorder; Known abnormally progressive sensorineural hearing loss; Currently participating, or participated within the last 30 days, in another clinical investigation involving an investigational drug or device that could impact the safety or effectiveness of the Sentio system as determined by the investigator; Use of active implantable or body worn devices that for medical reasons cannot be removed or discontinued, such as CSF shunts, implantable cardiac pacemakers, defibrillators, or neurostimulators; Known need for frequent MRI investigations for follow-up of other diseases; Current or known future use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator; Known retro cochlear pathology and auditory processing disorders that may have an impact on the outcome of the investigation; Any other known condition (e.g., developmental or learning delay or disability) that the investigator determines could interfere with compliance or investigation assessments; Any subject that according to the Declaration of Helsinki is deemed unsuitable for enrollment; Defined as >10 dB difference measured across PTA of .5, 1, 2, \& 3kHz
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 18 years old?
Where in United States
- Atlanta Institute for ENTAtlanta, United StatesContact: Jolie Fainberg, AuDTaking people
About the trial
What the trial wants to find out
This study is a post-market, multicentre, prospective, single arm investigation aimed to systematically collect safety and performance data on the Sentio system, when used as intended for adolescents (12-17 years inclusive).
The group in the trial
- subjects
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Sentio System: Post-market Evaluation of Safety and Performance in Adolescents With Mixed/Conductive Hearing Loss and Single Sided Deafness
- Plain-language title
- Sentio hearing system studied in teenagers with hearing loss or deafness in one earGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06844071, who can take part
- Record updated
- 22 September 2025